Physician

Sean Paul Lasalle, MD

According to 2025 Medicare claims, Sean Lasalle, MD (NPI: 1790715126) practices rheumatology in the Spokane-Spokane Valley, WA market, with the plurality of this provider's patient population coming from Spokane, WA. This provider's primary affiliated billing organization is ARTHRITIS NORTHWEST PLLC (NPI: 1558408104; TIN: 912152662) and primary practice location at 99216-1061. Lasalle is affiliated with the Kootenai Accountable Care, LLC (ACO ID: A3621), MultiCare Connected Care, LLC (ACO ID: A3631), Caravan Collaborative Pathways (ACO ID: A4604), Caravan Health ACO 50 LLC (ACO ID: A5160), PSW ACO (ACO ID: A5323), and Collaborative ACO 30, LLC (ACO ID: A5483), participating under the MSSP model.

Lasalle's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 858 traditional Medicare patients, billed 132,994 HCPCS/CPT codes, and received $2,585,932 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,251 prescription claims across 689 beneficiaries totaling $1,644,631 in drug costs, led by Humira(Cf) Pen (Adalimumab). Open Payments data shows 25 records totaling $63,295. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have risen steadily, from $784,569 to $1,644,631. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	700	76,396	$1,955,637
2016	777	76,510	$2,036,011
2017	799	65,922	$1,912,177
2018	735	72,857	$2,287,720
2019	740	82,363	$2,248,827
2020	768	96,795	$2,333,074
2021	802	89,873	$2,021,119
2022	677	86,277	$2,084,292
2023	722	99,924	$1,987,260
2024	858	132,994	$2,585,932

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	415	3,358	$784,569
2016	409	3,429	$907,832
2017	408	3,286	$1,054,421
2018	413	3,109	$1,175,229
2019	447	3,141	$1,402,364
2020	479	3,205	$1,454,664
2021	483	2,975	$1,395,352
2022	495	3,022	$1,636,197
2023	529	3,110	$1,584,282
2024	689	3,251	$1,644,631

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	610	947	$89
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	568	713	$13
80053	Blood test, comprehensive group of blood chemicals	492	1,042	$10
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	441	867	$8
86140	Measurement c-reactive protein for detection of infection or inflammation	453	982	$5

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Humira(Cf) Pen	Adalimumab	71	2,100	$516,195
Enbrel Sureclick	Etanercept	36	1,120	$297,791
Xeljanz Xr	Tofacitinib Citrate	24	780	$145,424
Enbrel	Etanercept	12	392	$105,488
Humira	Adalimumab	13	364	$88,107

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	17	$343	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	8	$62,952	E.R. Squibb & Sons, L.L.C.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Sean Paul Lasalle, MD?

Tedicare shows public-source Medicare data for Sean Paul Lasalle, MD (NPI 1790715126), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Sean Paul Lasalle, MD have ACO affiliation data?

Sean Paul Lasalle, MD is shown with ACO affiliation data for Kootenai Accountable Care, LLC (MSSP, ACO ID A3621), MultiCare Connected Care, LLC (MSSP, ACO ID A3631), Caravan Collaborative Pathways (MSSP, ACO ID A4604), Caravan Health ACO 50 LLC (MSSP, ACO ID A5160), PSW ACO (MSSP, ACO ID A5323), and Collaborative ACO 30, LLC (MSSP, ACO ID A5483).

What billing organization is linked to Sean Paul Lasalle, MD?

Sean Paul Lasalle, MD is linked to ARTHRITIS NORTHWEST PLLC (billing NPI 1558408104) in the available physician profile data.

Does Sean Paul Lasalle, MD have Open Payments data?

Sean Paul Lasalle, MD has 25 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.